Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752925 | 0.83 | KDM4E (0.39) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL5421781 | 0.79 | TAAR1 (0.38) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL3705107 | 0.79 | KMT2A (0.40) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL29882499 | 0.79 | KMT2A (0.40) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL15164736 | 0.76 | SMN1; SMN2 (0.31) | KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL25252301 | 0.76 | HSP90AA1 (0.37) | KDM4ECYP3A4CYP2C19KMT2AMEN1 | |
| SCHEMBL10451753 | 0.75 | KCNH2 (0.36) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL30096116 | 0.72 | HTT (0.44) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL23797878 | 0.71 | ALDH1A1 (0.36) | KDM4ECYP3A4CYP2C19HIF1AKMT2A | |
| SCHEMBL31292364 | 0.71 | CYP2C19 (0.33) | KDM4ECYP3A4CYP2C19HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | KDM4E 4725/4885CYP3A4 3017/4885CYP2C19 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.